Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 05, 2022 07:00 ET | Source: Aridis Pharmaceuticals, Inc.

Aridis Signs Exclusive Terms to Secure Worldwide Commercial Licenses for Pan-Ebola and Pan-Marburg Monoclonal Antibody Programs from Mapp Biopharmaceutical

The Sudan Ebola and Marburg mAb programs were awarded approximately $190 million of BARDA funding covering manufacturing, efficacy and safety evaluations, and regulatory approval Los Gatos, Calif.,...
November 30, 2022 07:00 ET | Source: Aridis Pharmaceuticals, Inc.

Aridis Announces a Key Milestone of Closing of Patient Enrollment in the Phase 2a Study of AR-501 in Cystic Fibrosis Patients

Los Gatos, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective...
November 22, 2022 09:10 ET | Source: Aridis Pharmaceuticals, Inc.

Aridis to Participate in Key Opinion Leader Discussion on Immunotherapy for Infectious Diseases

The Company’s superiority Phase 3 ‘ASAP-1' study of AR-301 monoclonal antibody in S. aureus pneumonia and the pending data readout will be a focus of the KOL event Los Gatos, Calif., Nov. 22, 2022 ...
November 21, 2022 18:30 ET | Source: Aridis Pharmaceuticals, Inc.

Aridis Pharmaceuticals Announces Third Quarter 2022 Financial Results and Business Update

Top-line data from the Phase 3 clinical trial evaluating AR-301 for the treatment of VAP expected in December of this year LOS GATOS, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aridis...

keyboard_arrow_left Previous Page